Lanitop® (Metildigoxin)

Metildigoxin inhibits the Na⁺/K⁺‑ATPase pump on heart muscle cells, leading to increased intracellular sodium. This change reduces calcium extrusion via the sodium‑calcium exchanger, resulting in higher intracellular calcium concentrations that strengthen myocardial contraction and enhance cardiac output.

The appropriate dose of Lanitop is individualized based on the patient’s clinical condition, renal function, electrolyte status, and response to therapy. The prescribing physician determines the exact regimen and may adjust it after therapeutic drug monitoring.

Safety data for Metildigoxin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Lanitop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lanitop (Metildigoxin) is chemically related to digoxin, the most widely used cardiac glycoside. Both share a similar mechanism of increasing intracellular calcium, but Metildigoxin may have a slightly different pharmacokinetic profile, potentially offering alternative dosing flexibility in certain patient populations.

Lanitop tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Lanitop is administered orally, usually with a glass of water. It may be taken with or without food, but consistency with respect to meals is recommended to avoid fluctuations in absorption.

The most serious risks include life‑threatening arrhythmias such as ventricular tachycardia, severe bradycardia or heart block, and marked electrolyte disturbances like hyperkalemia. Visual disturbances such as yellow‑green halos and confusion may also signal toxicity and require immediate medical attention.

Lanitop is contraindicated in patients with known hypersensitivity to Metildigoxin or other cardiac glycosides, those with uncontrolled ventricular arrhythmias, severe sinus node dysfunction without a pacemaker, and in individuals with acute myocardial infarction where increased contractility could be harmful.